CALHM1 anticorps (N-Term)

N° du produit ABIN1888041

Détail du produit anti-CALHM1 anticorps

Antigène: CALHM1 (Calcium Homeostasis Modulator 1 (CALHM1))

Épitope: N-Term

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CALHM1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Purification: Affinity chromatography purified via peptide column

Immunogène: 17 amino acid peptide near the amino terminus of human CALHM1.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS containing 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Conseil sur la manipulation: Avoid freezing and thawing repeatly.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 4 °C for short term use.Store at -20 °C for long term preservation.

Détails sur CALHM1

Antigène: CALHM1 (Calcium Homeostasis Modulator 1 (CALHM1))

Autre désignation: CALHM1 (CALHM1 Produits)

Synonymes: anticorps FAM26C, anticorps Fam26c, anticorps RGD1564891, anticorps EG546729, anticorps calcium homeostasis modulator 1, anticorps novel protein similar to vertebrate calcium homeostasis modulator protein family, anticorps CALHM1, anticorps LOC557535, anticorps Calhm1

Sujet: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP).The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels.While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link.CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.
Synonyms: Calcium homeostasis modulator 1, FAM26C

NCBI Accession: NP_001001412